Skip to search formSkip to main contentSkip to account menu

LY517717

Known as: LY 517717, LY-517717 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of… 
Review
2010
Review
2010
Drug discovery and development is an interdisciplinary, expensive and time-consuming process. Scientific advancements during the… 
Review
2009
Review
2009
Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary… 
Review
2008
Review
2008
In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chemistry, has… 
Review
2008
Review
2008
  • A. Turpie
  • European heart journal
  • 2008
  • Corpus ID: 16452979
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K… 
Review
2007
Review
2007
  • A. Turpie
  • Arteriosclerosis, thrombosis, and vascular…
  • 2007
  • Corpus ID: 2998452
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing… 
Highly Cited
2007
Highly Cited
2007
Summary.  Background: LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development. 
Review
2006
Review
2006
Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of… 
Review
2006
Review
2006
Novel anticoagulants to replace unfractionated heparins, low molecular weight heparins and vitamin K antagonists, are needed… 
Review
2005
Review
2005
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and…